Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration

Clinical and Experimental Ophthalmology

Volumn 41, Issue 8, 2013, Pages 723-726

  Wickremasinghe, Sanjeewa ^a   Abedi, Farshad ^a   Sandhu, Sukhpal S ^a   Guymer, Robyn ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; EDITORIAL; FEMALE; FOLLOW UP; HUMAN; MALE; RETINA MACULA AGE RELATED DEGENERATION; ANTAGONISTS AND INHIBITORS; DRUG ADMINISTRATION; RETREATMENT; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; HUMANS; RETREATMENT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84886286830     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12212     Document Type: Editorial

References (12)

1. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870.
2. Schmidt-Erfurth U, Eldem B, Guymer R etal. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118: 831-839.
3. Regillo CD, Brown DM, Abraham P etal. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-248.
4. Fung AE, Lalwani GA, Rosenfeld PJ etal. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
5. Holz FG, Amoaku W, Donate J etal. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118: 663-671.
6. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007; 143: 679-680.
7. Papadopoulos N, Martin J, Ruan Q etal. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-185.
8. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667-668.
9. Heier JS, Brown DM, Chong V etal. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548.
10. Lim JH, Wickremasinghe SS, Xie J etal. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012; 153: 678-686. 86 e1-2.
11. Abedi F, Wickremasinghe S, Richardson AJ etal. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 2013; 120: 115-121.
12. Wickremasinghe SS, Sandhu SS, Busija L, Lim J, Chauhan DS, Guymer RH. Predictors of AMD treatment response. Ophthalmology 2012; 119: 2413-2414 e5.